StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

NYSE:NSPR opened at $2.28 on Friday. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42. The stock’s fifty day moving average price is $2.60 and its two-hundred day moving average price is $2.57. The company has a market cap of $56.84 million, a price-to-earnings ratio of -3.08 and a beta of 0.93.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.